GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma Q2 FY27 Standalone Profit After Tax at ₹7,235.8 million

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 08:48 PM IST  ·  BSE ID: 5d35cc14-464d-40c2-b13b-658a43fecdd9
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma's Board approved Q2 FY27 results, declared a Rs. 7.00 per share interim dividend, and initiated a subsidiary merger.
🤖 AI Summary
  • Board approved standalone and consolidated unaudited financial results for Q2 FY27 and half year ended September 30, 2026.
  • Interim dividend of 700%, equivalent to Rs. 7.00 per equity share of Re. 1/-, was declared.
  • Record date for interim dividend is November 11, 2026, with payment on or before November 20, 2026.
  • Scheme of Amalgamation for Auroactive Pharma Private Limited with Apitoria Pharma Private Limited was approved.
  • Proposed re-appointment of Mr. Mangalam Ramasubramanian Kumar as Independent Director for a second 5-year term.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Profit After Tax from continuing operations Q2 FY27
₹7,235.8 million
Profit After Tax from continuing operations Q2 FY26
₹5,822.4 million
Total Revenue from operations Q2 FY27
₹31,773.3 million
Total Revenue from operations Q2 FY26
₹27,299.3 million
Interim Dividend per equity share
Rs. 7.00
Basic EPS for total operations Q2 FY27
₹12.58
Basic EPS for total operations Q2 FY26
₹10.01
🏢 How This Affects the Company
📈
Business Impact
The proposed amalgamation of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited aims to streamline subsidiary operations. The transfer of Auro Pharma LLC, Russia, to Auropharm Overseas Limited shifts ownership within the wholly-owned subsidiary structure.
💰
Financial Impact
The interim dividend of Rs. 7.00 per equity share will result in an outflow of funds to shareholders. Standalone Profit After Tax from continuing operations for Q2 FY27 was ₹7,235.8 million, contributing to the half-year PAT of ₹14,608.0 million.
⚙️
Operational Impact
The amalgamation of two wholly-owned subsidiaries could lead to operational efficiencies and consolidation benefits. Re-appointment of a Non-executive and Independent Director maintains board continuity and oversight.
👥 What This Means For Shareholders
✅
Action Required
Shareholders wishing to receive the interim dividend must ensure their shares are in their demat account by the record date of November 11, 2026.
👤
Who Is Affected
Shareholders on record as of November 11, 2026, will receive an interim dividend of Rs. 7.00 per equity share. The re-appointment of Mr. Mangalam Ramasubramanian Kumar requires approval via Postal Ballot.
🔍
Management Signal
The declaration of a substantial interim dividend signals management's confidence in financial performance and commitment to shareholder returns. The subsidiary amalgamation indicates a focus on corporate restructuring and operational synergy.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor revenue and profit after tax trends.
Record date for interim dividend — ensure shares are held by November 11, 2026.
NCLT proceedings for subsidiary amalgamation — track scheme approval status.
LOW RISK No new significant risks identified; routine corporate actions and positive financial results.
💡 Investor Takeaway
Aurobindo Pharma reported standalone Profit After Tax from continuing operations of ₹7,235.8 million for Q2 FY27, an increase from ₹5,822.4 million in Q2 FY26. Revenue from operations also rose to ₹31,773.3 million. The Board declared an interim dividend of 700% (Rs. 7.00 per share) with a record date of November 11, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit After Tax from continuing operations for Q2 FY27 was ₹7,235.8 million, up from ₹5,822.4 million in Q2 FY26.
  • Revenue from operations increased to ₹31,773.3 million in Q2 FY27 from ₹27,299.3 million in Q2 FY26.

⚠️ Concerns

  • Employee benefits expense increased to ₹3,000.7 million in Q2 FY27 from ₹2,768.2 million in Q2 FY26.
  • Other expenses rose to ₹4,314.6 million in Q2 FY27, compared to ₹3,868.2 million in Q2 FY26.
📅 Company Track Record
Aurobindo Pharma's Q2 FY27 standalone net profit increased to INR 1,124 Cr, up 32.5% YoY, following Q1 FY27 net profit of INR 1,032 Cr, which rose 25.2% YoY. Q1 FY26 Profit After Tax was ₹7,372.2 million, up 31.85%. This filing shows continued positive growth in profit.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Aurobindo Pharma's standalone Profit After Tax for Q2 FY27?
Aurobindo Pharma reported a standalone Profit After Tax from continuing operations of ₹7,235.8 million for the quarter ended September 30, 2026 (Q2 FY27).
What interim dividend did Aurobindo Pharma declare for FY27?
The Board approved an interim dividend of 700%, which is Rs. 7.00 per equity share of Re.1/- each. The record date for this dividend is November 11, 2026.
When will Aurobindo Pharma pay the interim dividend?
The interim dividend will be paid on or before November 20, 2026, to eligible shareholders.
What was Aurobindo Pharma's total revenue from operations in Q2 FY27?
Total revenue from operations for Aurobindo Pharma in Q2 FY27 was ₹31,773.3 million, up from ₹27,299.3 million in Q2 FY26.
What corporate restructuring did Aurobindo Pharma's Board approve?
The Board approved a Scheme of Amalgamation for the merger of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited, both wholly-owned subsidiaries.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.